ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $103.43 Average Price Target from Brokerages

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has earned a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $103.4286.

ANIP has been the subject of a number of research analyst reports. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Barclays began coverage on shares of ANI Pharmaceuticals in a research report on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 target price for the company. Truist Financial boosted their price target on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a research report on Thursday, October 9th. Guggenheim raised their price objective on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a report on Friday, January 16th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th.

Insider Activity at ANI Pharmaceuticals

In related news, SVP Krista Davis sold 1,622 shares of the company’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $82.40, for a total value of $133,652.80. Following the sale, the senior vice president directly owned 58,564 shares of the company’s stock, valued at $4,825,673.60. This represents a 2.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Meredith Cook sold 500 shares of the firm’s stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $84.33, for a total value of $42,165.00. Following the transaction, the vice president directly owned 74,374 shares of the company’s stock, valued at $6,271,959.42. This represents a 0.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 28,101 shares of company stock valued at $2,453,063 over the last ninety days. Insiders own 12.70% of the company’s stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Hantz Financial Services Inc. lifted its holdings in shares of ANI Pharmaceuticals by 202.6% during the third quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock valued at $32,000 after purchasing an additional 237 shares during the last quarter. Advisors Asset Management Inc. bought a new position in ANI Pharmaceuticals during the 1st quarter valued at approximately $28,000. Caitong International Asset Management Co. Ltd increased its position in ANI Pharmaceuticals by 4,636.4% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company’s stock valued at $34,000 after buying an additional 510 shares in the last quarter. Newbridge Financial Services Group Inc. raised its stake in ANI Pharmaceuticals by 200.0% during the second quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock valued at $39,000 after buying an additional 400 shares during the last quarter. Finally, State of Wyoming bought a new stake in ANI Pharmaceuticals in the second quarter worth $50,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ:ANIP opened at $80.00 on Friday. The company has a current ratio of 2.58, a quick ratio of 2.04 and a debt-to-equity ratio of 1.20. The company has a 50-day moving average price of $81.88 and a 200-day moving average price of $85.30. The company has a market cap of $1.80 billion, a price-to-earnings ratio of 49.08 and a beta of 0.50. ANI Pharmaceuticals has a 12 month low of $54.10 and a 12 month high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.74 by $0.30. The company had revenue of $227.81 million for the quarter, compared to analysts’ expectations of $211.92 million. ANI Pharmaceuticals had a return on equity of 26.73% and a net margin of 4.91%.ANI Pharmaceuticals’s quarterly revenue was up 53.6% on a year-over-year basis. During the same period last year, the firm earned $1.34 earnings per share. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. As a group, equities analysts anticipate that ANI Pharmaceuticals will post 3.86 EPS for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.